A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice
Abstract
:1. Introduction
2. Results
2.1. Tripartite Treatment Augments the Anti-tumor Response
2.2. Tripartite Treatment Increases Animal Survival with No Treatment-Related Toxicity
2.3. Tripartite Therapy Potentiates Tumor-Targeting T-Cell Infiltration and Activation in the Tumor Microenvironment
2.4. Tripartite Treatment Does Not Alter the Myeloid Derived Suppressor Cells in the PC-TME
3. Discussion
4. Methods
4.1. Development of Syngeneic Subcutaneous Tumor Model
4.2. Tumor Targeted Hyperthermia (HT)
4.3. Tumor Targeted Radiation (RT)
4.4. Immunotherapeutic Treatment (IT)
4.5. Flow Cytometry
4.6. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [Google Scholar] [CrossRef] [PubMed]
- Oettle, H. Progress in the knowledge and treatment of advanced pancreatic cancer: From bench side to bedside. Cancer Treat. Rev. 2014, 40, 1039–1047. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sandberg, A.A. Pancreatic cancer: Chemotherapy and radiotherapy. N. Am. J. Med. Sci. 2011, 3, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Balaban, E.P.; Mangu, P.B.; Yee, N.S. Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. J. Oncol. Pract. 2017, 13, 265–269. [Google Scholar] [CrossRef] [PubMed]
- Boone, B.A.; Steve, J.; Krasinskas, A.M.; Zureikat, A.H.; Lembersky, B.C.; Gibson, M.K.; Stoller, R.G.; Zeh, H.J.; Bahary, N. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J. Surg. Oncol. 2013, 108, 236–241. [Google Scholar] [CrossRef] [Green Version]
- Jones, O.P.; Melling, J.D.; Ghaneh, P. Adjuvant therapy in pancreatic cancer. World J. Gastroenterol. 2014, 20, 14733–14746. [Google Scholar] [CrossRef]
- Formenti, S.C. On the promise of combining radiotherapy and immunotherapy to treat cancer. Oncology (Williston Park) 2016, 30, 289–292. [Google Scholar] [PubMed]
- Kaur, P.; Asea, A. Radiation-induced effects and the immune system in cancer. Front. Oncol. 2012, 2, 191. [Google Scholar] [CrossRef] [Green Version]
- Dovedi, S.J.; Cheadle, E.J.; Popple, A.L.; Poon, E.; Morrow, M.; Stewart, R.; Yusko, E.C.; Sanders, C.M.; Vignali, M.; Emerson, R.O.; et al. Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. Clin. Cancer Res. 2017, 23, 5514–5526. [Google Scholar] [CrossRef] [Green Version]
- Mahmood, J.; Shukla, H.D.; Soman, S.; Samanta, S.; Singh, P.; Kamlapurkar, S.; Saeed, A.; Amin, N.P.; Vujaskovic, Z. Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment. Cancers 2018, 10, 469. [Google Scholar] [CrossRef] [Green Version]
- Skitzki, J.J.; Repasky, E.A.; Evans, S.S. Hyperthermia as an immunotherapy strategy for cancer. Curr. Opin. Investig. Drugs 2009, 10, 550–558. [Google Scholar] [PubMed]
- Shevtsov, M.; Multhoff, G. Heat Shock Protein–Peptide and HSP-Based Immunotherapies for the Treatment of Cancer. Front. Immunol. 2016, 7, 171. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Anderson, K.G.; Stromnes, I.M.; Greenberg, P.D. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell 2017, 31, 311–325. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Amrutkar, M.; Gladhaug, I.P. Pancreatic Cancer Chemoresistance to Gemcitabine. Cancers 2017, 9, 157. [Google Scholar] [CrossRef] [Green Version]
- Liu, Q.; Liao, Q.; Zhao, Y. Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int. 2017, 17, 68. [Google Scholar] [CrossRef] [Green Version]
- Ireland, L.; Santos, A.; Ahmed, M.S.; Rainer, C.; Nielsen, S.R.; Quaranta, V.; Weyer-Czernilofsky, U.; Engle, D.D.; Perez-Mancera, P.A.; Coupland, S.E.; et al. Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors. Cancer Res. 2016, 76, 6851–6863. [Google Scholar] [CrossRef] [Green Version]
- Schmidtner, J.; Distel, L.V.; Ott, O.J.; Nkenke, E.; Sprung, C.N.; Fietkau, R.; Lubgan, D. Hyperthermia and irradiation of head and neck squamous cancer cells causes migratory profile changes of tumor infiltrating lymphocytes. Int. J. Hyperth. 2009, 25, 347–354. [Google Scholar] [CrossRef]
- Wei, Z.; Zhan, X.; Fan, L.; Ye, X.; Yang, X.; Huang, G.; Li, W.; Wang, J.; Han, X.; Meng, M.; et al. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy. Int. J. Hyperth. 2018, 35, 591–598. [Google Scholar] [CrossRef]
- Yagawa, Y.; Tanigawa, K.; Kobayashi, Y.; Yamamoto, M. Cancer immunity and therapy using hyperthermia with immunotherapy, radiotherapy, chemotherapy, and surgery. Cancer Metastasis Treat. 2017, 3, 218–230. [Google Scholar] [CrossRef]
- Macherla, S.; Laks, S.; Naqash, A.R.; Bulumulle, A.; Zervos, E.; Muzaffar, M. Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. Int. J. Mol. Sci. 2018, 19, 3505. [Google Scholar] [CrossRef] [Green Version]
- Cheng, X.; Zhao, G.; Zhao, Y. Combination Immunotherapy Approaches for Pancreatic Cancer Treatment. Can. J. Gastroenterol. Hepatol. 2018, 2018, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rosenberg, A.; Mahalingam, D. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. J. Gastrointest. Oncol. 2018, 9, 143–159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- So, T.; Lee, S.W.; Croft, M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 2008, 19, 253–262. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Polesso, F.; Weinberg, A.; Moran, A.E. Late stage tumor regression after PD-L1 blockade with a concurrent OX40 agonist. Cancer Immunol. Res. 2018, 222, 2018. [Google Scholar] [CrossRef] [PubMed]
- Aspeslagha, S.; Postel-Vinaya, S.; Rusakiewiczc, S.; Soriaa, J.-C.; Zitvogela, L.; Marabelle, A. Rationale for anti-OX40 cancer immunotherapy. Eur. J. Cancer 2016, 52, 50–66. [Google Scholar] [CrossRef]
- Sagiv-Barfi, I.; Czerwinski, D.K.; Levy, S.; Alam, I.S.; Mayer, A.T.; Gambhir, S.S.; Levy, R. Eradication of spontaneous malignancy by local immunotherapy. Sci. Transl. Med. 2018, 10, 426. [Google Scholar] [CrossRef] [Green Version]
- Wu, F. High intensity focused ultrasound: A noninvasive therapy for locally advanced pancreatic cancer. World J. Gastroenterol. 2014, 20, 16480–16488. [Google Scholar] [CrossRef]
- van der Zee, J.; González González, D.; van Rhoon, G.C.; van Dijk, J.D.; van Patten, W.L.; Hart, A.A. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: A prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000, 355, 1119–1125. [Google Scholar] [CrossRef]
- Colombo, R.; Da Pozzo, L.F.; Salonia, A.; Rigatti, P.; Leib, Z.; Baniel, J.; Caldarera, E.; Pavone-Macaluso, M. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J. Clin. Oncol. 2003, 21, 4270–4276. [Google Scholar] [CrossRef]
- Maluta, S.; Schaffer, M.; Pioli, F.; Dall’Oglio, S.; Pasetto, S.; Schaffer, P.M.; Weber, B.; Giri, M.G. Regional hyperthermia combined with chemoradiotherapy in primary or recurrent locally advanced pancreatic cancer: An open-label comparative cohort trial. Strahlentherapie Onkologie 2011, 187, 619. [Google Scholar] [CrossRef]
- van der Horst, A.; Versteijne, E.; Besselink, M.G.; Daams, J.G.; Bulle, E.B.; Bijlsma, M.F.; Wilmink, J.W.; van Delden, O.M.; van Hooft, J.E.; Franken, N.A.; et al. The clinical benefit of hyperthermia in pancreatic cancer: A systematic review. Int. J. Hyperth. 2018, 34, 969–979. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seidel, J.A.; Otsuka, A.; Kabashima, K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol. 2018, 8, 86. [Google Scholar] [CrossRef]
- Marin-Acevedo, J.A.; Dholaria, B.; Soyano, A.E.; Knutson, K.L.; Chumsri, S.; Lou, Y. Next generation of immune checkpoint therapy in cancer: New developments and challenges. J. Hematol. Oncol. 2018, 11, 39. [Google Scholar] [CrossRef] [PubMed]
- Feig, C.; Gopinathan, A.; Neesse, A.; Chan, D.S.; Cook, N.; Tuveson, D.A. The pancreas cancer microenvironment. Clin. Cancer Res. 2012, 18, 4266–4276. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oberstein, P.E.; Olive, K.P. Pancreatic cancer: Why is it so hard to treat? Ther. Adv. Gastroenterol. 2013, 6, 321–337. [Google Scholar] [CrossRef] [Green Version]
- Pillarisetty, V.G. The pancreatic cancer microenvironment: An immunologic battleground. Oncoimmunology 2014, 3, e950171. [Google Scholar] [CrossRef]
- Guo, S.; Contratto, M.; Miller, G.; Leichman, L.; Wu, J. Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World J. Clin. Oncol. 2017, 8, 230–240. [Google Scholar] [CrossRef]
- Young, K.; Hughes, D.J.; Cunningham, D.; Starling, N. Immunotherapy and pancreatic cancer: Unique challenges and potential opportunities. Ther. Adv. Med. Oncol. 2018, 10, 1758835918816281. [Google Scholar] [CrossRef] [Green Version]
- Linch, S.N.; McNamara, M.J.; Redmond, W.L. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. Front. Oncol. 2015, 5, 34. [Google Scholar] [CrossRef] [Green Version]
- Foley, K.; Kim, V.; Jaffee, E.; Zheng, L. Current progress in immunotherapy for pancreatic cancer. Cancer Lett. 2016, 381, 244–251. [Google Scholar] [CrossRef] [Green Version]
- Torphy, R.J.; Zhu, Y.; Schulick, R.D. Immunotherapy for pancreatic cancer: Barriers and breakthroughs. Ann. Gastroenterol. Surg. 2018, 2, 274–281. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Johansson, H.; Andersson, R.; Bauden, M.; Hammes, S.; Holdenrieder, S.; Ansari, D. Immune checkpoint therapy for pancreatic cancer. World J. Gastroenterol. 2016, 22, 9457–9476. [Google Scholar] [CrossRef] [PubMed]
- Ma, C.M.; Coffey, C.W.; DeWerd, L.A.; Liu, C.; Nath, R.; Seltzer, S.M.; Seuntjens, J.P. AAPM protocol for 40–300 kV x-ray beam dosimetry in radiotherapy and radiobiology. Med. Phys. 2001, 28, 868–893. [Google Scholar] [CrossRef] [PubMed]
- Guo, Z.; Wang, X.; Cheng, D.; Xia, Z.; Luan, M.; Zhang, S. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS ONE 2014, 9, e89350. [Google Scholar] [CrossRef] [PubMed]
- Chuong, M.; Chang, E.T.; Choi, E.Y.; Mahmood, J.; Lapidus, R.G.; Davila, E.; Carrier, F. Exploring the concept of radiation “booster shot” in combination with an anti-PD-L1 mAb to enhance anti-tumor immune effects in mouse pancreas tumors. JSM Clin. Oncol. Res. 2017, 5, 1058. [Google Scholar]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mahmood, J.; Alexander, A.A.; Samanta, S.; Kamlapurkar, S.; Singh, P.; Saeed, A.; Carrier, F.; Cao, X.; Shukla, H.D.; Vujaskovic, Z. A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice. Cancers 2020, 12, 1015. https://doi.org/10.3390/cancers12041015
Mahmood J, Alexander AA, Samanta S, Kamlapurkar S, Singh P, Saeed A, Carrier F, Cao X, Shukla HD, Vujaskovic Z. A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice. Cancers. 2020; 12(4):1015. https://doi.org/10.3390/cancers12041015
Chicago/Turabian StyleMahmood, Javed, Allen A. Alexander, Santanu Samanta, Shriya Kamlapurkar, Prerna Singh, Ali Saeed, France Carrier, Xuefang Cao, Hem D Shukla, and Zeljko Vujaskovic. 2020. "A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice" Cancers 12, no. 4: 1015. https://doi.org/10.3390/cancers12041015